- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04672317
Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma
A Prospective, Open Clinical Study to Examine the Efficacy and Safety of Neoadjuvant Tislelizumab Combined With Cisplatin-based Chemotherapy in Patients With Locally Advanced Upper Urinary Tract Urothelial Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Shanghai Renji Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Patients that are identified as locally advanced upper urinary tract urothelial carcinoma by ureteroscopic biopsy and imaging diagnosis and are determined as appropriate candidates for radical nephrectomy by an attending urologist; 2. Patients who have a clinical stage of T3-T4, any N, M0 or any T, N1-2, M0; 3. ECOG performance status of 0 to 2; 4. Adequate organ function defined by study-specified laboratory tests;
- Hemoglobin ≥90 g/L;
- Hematological Absolute neutrophil count (ANC) ≥1.5×109 /L;
- Platelets ≥100×109 /L 5. No functional organic disease: T-BIL≤1.5×upper limit of normal (ULN); ALT and AST≤2.5×ULN;eGFR ≥ 60ml/min (MdRD) 6. Agree to comply with scheduled visits, treatment plans, lab tests and any other required study procedures;
Exclusion Criteria:
- Patients who has received prior therapy of an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody;
- Patients who are allergic to monoclonal antibodies or any of its excipients;
- Patients who have received other anti-tumor treatment (e. g., Steroid therapy, immunotherapy) within 4 weeks or enrolled in other clinical trials;
- Patients who are pregnant or breastfeeding, or expecting to conceive;
- Patients who have a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies);
- Patients who have known active Hepatitis B or Hepatitis C;
- Patients who have active autoimmune disease that has required systemic treatment in the past 2 years;
- Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment;
- Patients who have received prior radiation therapy to the bladder;
- Patients who have bladder cancer;
- Patients who have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
- Patients who have a history of substance abuse or with a history of mental disorders;
- Patients who had other malignant tumors in the past five years that have not recovered except for curable tumors that have been cured including basal or squamous skin cancer, localized carcinoma in situ of the cervix or the breast or low-risk prostate cancer, etc;Patients who have active tuberculosis;
- Patients who have other serious and uncontrollable accompanying diseases that may affect compliance or interfere with the interpretation of results including active opportunistic infections or advanced (severe) infections, uncontrollable diabetes, cardiovascular disease (grade III or IV heart failure defined by the New York Heart Association classification, II degree atrioventricular block and above, myocardial infarction in the past 6 months, unstable arrhythmia or instability angina, cerebral infarction within 3 months, etc.) or lung disease (interstitial pneumonia, history of obstructive lung disease and symptomatic bronchospasm);
- Patients who have a large amount of pleural fluid or ascites with clinical symptoms or requiring symptomatic treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neoadjuvant arm
Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy. Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible. Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy |
Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy. Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Other Names: • anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible. Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological complete response rate
Time Frame: 30 days after surgery
|
the absence of visible lesion of carcinoma (ypT0/Tis) and the absence of microscopic lymph node metastases (ypN0) on the final surgical specimen
|
30 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic response rate
Time Frame: 30 days after surgery
|
The rate of patients that reach pathological downstaging at the time of nephroureterectomy.
|
30 days after surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTUC-NEOCI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoadjuvant Therapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma
-
RenJi HospitalCompletedNeoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial CarcinomaChina
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial CarcinomaUnited States
-
RenJi HospitalXiangya Hospital of Central South University; Shanghai Zhongshan Hospital; West... and other collaboratorsRecruitingUpper Tract Urothelial Carcinoma Receiving Kidney-sparing TherapyChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar TherapeuticsRecruitingLocally Advanced or Metastatic Urothelial CarcinomaKorea, Republic of, United States, Taiwan, Australia, United Kingdom, France, Greece, Italy, Belgium, Spain, Canada, Denmark, Germany
-
AstraZenecaActive, not recruitingMetastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial CancerUnited States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingNeoadjuvant Therapy | High Risk Prostate Cancer | Locally Advanced Prostate Cancer | Intense Endocrine TherapyChina
-
RenJi HospitalCompletedNeoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell CarcinomaChina
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditionsUnited States
Clinical Trials on Immunotherapy combined with chemotherapy
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
ShiCang YuRecruiting
-
Zhejiang Cancer HospitalRecruitingMetastatic Breast Cancer in the LiverChina
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingEfficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) HNSCCChina
-
Yantai Yuhuangding HospitalRecruiting
-
Fudan UniversityNot yet recruitingAdvanced Rectal Cancer | Liver Metastasis | Pulmonary Metastasis | Microsatellite Stable Colorectal CarcinomaChina
-
Yantai Yuhuangding HospitalRecruiting
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsCompletedMetastatic Esophageal Squamous Cell CarcinomaChina
-
Shanghai Chest HospitalRecruitingNon-small Cell Lung Cancer | Minimal Residual Disease | Immunotherapy | Anti-angiogenesisChina
-
The Second Affiliated Hospital of Shandong First...Recruiting